Similarly, CD4+ cells from patients with stage I renal carcinoma showed predominantly Th1-polarized responses to EphA2, whereas CD4+ cells from later stages showed progressively more Th2-polarized responses (Tatsumi et al., 2003). The gene discussed is CD4; the disease is renal carcinoma.